ICER Announces Upcoming Value-Assessment for Pulmonary Arterial Hypertension Treatment
May 15, 2023
The Institute for Clinical and Economic Review (ICER) has announced it will perform a value-assessment for Merck’s sotatercept for the treatment of pulmonary arterial hypertension. The organization has been in talks with patient groups, clinical specialists, manufacturers, and patient advocates and will present its report at the Midwest CEPAC meeting this coming December.
According to ICER, “All interested stakeholders are encouraged to submit comments and suggested refinements to the scope to ensure all perspectives are adequately considered. Comments can be submitted by email to publiccomments@icer.org and must be received by 5 PM ET on June 5, 2023.”
To read more, click here.
(Source: ICER, May 15th, 2023)
